Literature DB >> 15751266

An economic model to reduce the cost of chemotherapy for gynecologic cancer.

Volker R Jacobs1, Jutta Thoedtmann, Bettina Brunner, Marion Kiechle.   

Abstract

OBJECTIVE: Chemotherapy with innovative state-of-the-art medicine at university level can be very costly. Reimbursement until 2002 was at a flat rate, often not even covering the costs of the pharmaceutical substances. To avoid debt a more cost-effective chemotherapy management system had to be found.
MATERIALS AND METHODS: From this background, an economic model with four steps was developed: 1. Analysis of current financial situation; 2. Precalculation of chemotherapy costs; 3. Assignment to an individual cost-covering reimbursement pathway; and 4. Postcalculation for cost efficiency and elimination of potential mistakes.
RESULTS: After successful implementation of this model we were able to reach cost effectiveness for our chemo unit within 12 months and pay back previous debts and were even able to employ new medical staff.
CONCLUSION: With this model we are now able to perform chemotherapy cost effectively at a university level without reducing standard of care.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15751266

Source DB:  PubMed          Journal:  Int J Fertil Womens Med        ISSN: 1534-892X


  3 in total

1.  Financial Quality Control of In-Patient Chemotherapy in Germany: Are Additional Payments Cost-Covering for Pharmaco-Oncological Expenses?

Authors:  Volker R Jacobs; Peter Mallmann
Journal:  Breast Care (Basel)       Date:  2011-04-29       Impact factor: 2.860

Review 2.  Relevance of health economics in breast cancer treatment: integration of economics in the management of breast cancer at the clinic level.

Authors:  Volker R Jacobs; Gerhard Bogner; Christiane E Schausberger; Roland Reitsamer; Thorsten Fischer
Journal:  Breast Care (Basel)       Date:  2013-03       Impact factor: 2.860

Review 3.  A pragmatic guide on how physicians can take over financial control of their clinical practice.

Authors:  Volker R Jacobs; Thorsten Fischer
Journal:  JSLS       Date:  2012 Oct-Dec       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.